INM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
InMed Pharmaceuticals's book value per share for the quarter that ended in Mar. 2024 was $1.75.
During the past 12 months, InMed Pharmaceuticals's average Book Value Per Share Growth Rate was -53.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -49.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -45.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of InMed Pharmaceuticals was 529.50% per year. The lowest was -75.10% per year. And the median was 16.80% per year.
InMed Pharmaceuticals's current price is $0.2354. Its book value per share for the quarter that ended in Mar. 2024 was $1.75. Hence, today's PB Ratio of InMed Pharmaceuticals is 0.13.
During the past 13 years, the highest P/B Ratio of InMed Pharmaceuticals was 1.31. The lowest was 0.11. And the median was 0.25.
Good Sign:
InMed Pharmaceuticals Inc stock PB Ratio (=0.13) is close to 1-year low of 0.13
The historical data trend for InMed Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 66.48 | 28.15 | 22.91 | 13.95 | 3.63 |
InMed Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Book Value per Share | Get a 7-Day Free Trial | 3.72 | 3.63 | 2.88 | 2.25 | 1.75 |
For the Biotechnology subindustry, InMed Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's PB Ratio falls into.
InMed Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (12.09 | - | 0.00) | / | 3.33 | |
= | 3.63 |
InMed Pharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (11.11 | - | 0.00) | / | 6.34 | |
= | 1.75 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
InMed Pharmaceuticals (NAS:INM) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of InMed Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan Tegge | officer: Interim CFO | 217 W. MAIN STREET, SOMERVILLE NJ 08876 |
Sarah Li | officer: VP, Accounting and Controller | 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4 |
Nicole Lemerond | director | 3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
Bryan T Baldasare | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric A Adams | director, officer: President & CEO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Brenda Edwards | officer: Interim CFO | 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2 |
Janet P Grove | director | 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5 |
Bruce Colwill | officer: CFO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Shane Aaron Johnson | officer: SVP & GM of BayMedica LLC | 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451 |
Adam D. Cutler | director | 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
Catherine Sazdanoff | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric C Hsu | officer: Sr. VP, Pre-Clinical Res/Dev | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Michael Woudenberg | officer: VP, Chem/Manufacturing/Control | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Mancini Alexandra Diane Janet | officer: Sr VP, Clinical Reg Affairs | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-19-2022
By Stock market mentor Stock market mentor • 01-10-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By Value_Insider Value_Insider • 11-17-2022
By Value_Insider Value_Insider • 11-18-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
By GlobeNewswire GlobeNewswire • 11-21-2022
By PurpleRose PurpleRose • 07-12-2022
By Value_Insider Value_Insider • 11-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.